The Endocrine Society’s Journal of the Endocrine Society (JES) received its first Impact Factor score in 2022, while the Society’s other journals maintained high rankings on the prestigious measure of scholarly publishing.
NGM Bio to revert to private company as MASH potential remains unclear
Sixteen years after announcing it led NGM Bio’s $25.5 million Series A, biotech investor The Column Group now plans to take the drug development company